Payment overview · 2025
General Payments
$2,051.71
67 reported records · 17 companies
Healthcare provider profile · identity verified
Muna N Jabbour, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW STANTON, PA · NPI 1679535751
Verified facts
What the public records show
CMS Open Payments records show Muna N Jabbour, M.D. received $2,051.71 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Invega Sustenna, Ozempic, Shingrix, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 536 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $880.41 | 42.9% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $324.40 | 15.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $229.49 | 11.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.88 | 4.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.92 | 4.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.40 | 3.3% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.64 | 3.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.38 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.77 | 2.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.14 | 1.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $31.81 | 1.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.56 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.86 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.40 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.86 | 0.9% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.64 | 0.8% | 1 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $15.15 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,051.71 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $505.79 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $370.53 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $157.99 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.25 | 6 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $116.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $96.88 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.88 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.40 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $64.64 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.51 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $51.77 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.65 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.15 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $6.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 32 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 536 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
290 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
32 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
536 | 86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1260 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 764 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 762 | 170 |
| Pantoprazole Sodium | Pantoprazole Sodium | 651 | 157 |
| Gabapentin | Gabapentin | 570 | 106 |
| Eliquis | Apixaban | 536 | 86 |
| Lisinopril | Lisinopril | 536 | 128 |
| Furosemide | Furosemide | 528 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 513 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 508 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 493 | 91 |
| Potassium Chloride | Potassium Chloride | 462 | 91 |
| Omeprazole | Omeprazole | 357 | 77 |
| Sertraline Hcl | Sertraline Hcl | 356 | 54 |
| Metformin Hcl | Metformin Hcl | 339 | 85 |
| Simvastatin | Simvastatin | 305 | 63 |
| Losartan Potassium | Losartan Potassium | 302 | 73 |
| Xarelto | Rivaroxaban | 290 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 283 | 56 |
| Bumetanide | Bumetanide | 278 | 59 |
| Warfarin Sodium | Warfarin Sodium | 265 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 261 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 238 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 226 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 48 |
| Famotidine | Famotidine | 217 | 56 |
| Trazodone Hcl | Trazodone Hcl | 208 | 36 |
| Donepezil Hcl | Donepezil Hcl | 203 | 32 |
| Allopurinol | Allopurinol | 200 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 189 | 70 |
| Levetiracetam | Levetiracetam | 182 | 30 |
| Finasteride | Finasteride | 173 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 35 |
| Meloxicam | Meloxicam | 165 | 29 |
| Carvedilol | Carvedilol | 160 | 36 |
| Risperidone | Risperidone | 158 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 52 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 151 | 85 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 19 |
| Spironolactone | Spironolactone | 134 | 29 |
| Tramadol Hcl | Tramadol Hcl | 132 | 33 |
| Mirtazapine | Mirtazapine | 125 | 30 |
| Divalproex Sodium | Divalproex Sodium | 123 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 122 | 30 |
| Novolog Flexpen | Insulin Aspart | 122 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 118 | 12 |
| Montelukast Sodium | Montelukast Sodium | 118 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 36 |
| Ibuprofen | Ibuprofen | 111 | 31 |
| Cephalexin | Cephalexin | 103 | 56 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 101 | 24 |
| Lorazepam | Lorazepam | 99 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 95 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 23 |
| Alendronate Sodium | Alendronate Sodium | 85 | 19 |
| Clonazepam | Clonazepam | 84 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | 16 |
| Amantadine | Amantadine Hcl | 81 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 26 |
| Januvia | Sitagliptin Phosphate | 80 | 11 |
| Ozempic | Semaglutide | 77 | 17 |
| Valsartan | Valsartan | 76 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 74 | 24 |
| Clonidine Hcl | Clonidine Hcl | 74 | 22 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Lacosamide | Lacosamide | 72 | suppressed |
| Prednisone | Prednisone | 72 | 27 |
| Atenolol | Atenolol | 69 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 15 |
| Midodrine Hcl | Midodrine Hcl | 69 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 66 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 38 |
| Lactulose | Lactulose | 65 | suppressed |
| Jardiance | Empagliflozin | 64 | 11 |
| Glimepiride | Glimepiride | 63 | 18 |
| Enulose | Lactulose | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 11 |
| Synthroid | Levothyroxine Sodium | 62 | 15 |
| Amoxicillin | Amoxicillin | 61 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 21 |
| Azithromycin | Azithromycin | 57 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | 12 |
| Baclofen | Baclofen | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 50 | 34 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 32 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 48 | suppressed |
| Mupirocin | Mupirocin | 48 | 25 |
| Xifaxan | Rifaximin | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 12 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Glipizide | Glipizide | 43 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Haloperidol | Haloperidol | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 21 |
| Topiramate | Topiramate | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 38 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Nystatin | Nystatin | 35 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 32 | 18 |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 16 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Acetic Acid | Acetic Acid | 26 | 12 |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Cimetidine | Cimetidine | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Admelog Solostar | Insulin Lispro | 20 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 14 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | 16 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Tobramycin | Tobramycin | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,051.71 · 67 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BOTOX, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, EMBLAVEO, FARXIGA, GARDASIL 9, INVEGA SUSTENNA, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, UZEDY, VRAYLAR, Wegovy, XIFAXAN, Xeomin, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error